Omeros Co. (NASDAQ:OMER) Receives Average Rating of "Moderate Buy" from Brokerages

Omeros Co. (NASDAQ:OMER - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the five brokerages that are currently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $22.50.

A number of research firms have commented on OMER. D. Boral Capital reiterated a "buy" rating and issued a $36.00 price target on shares of Omeros in a research report on Tuesday, May 13th. Needham & Company LLC reissued a "hold" rating on shares of Omeros in a research note on Friday, May 16th. Finally, Wall Street Zen raised Omeros from a "sell" rating to a "hold" rating in a research note on Monday, May 19th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Acadian Asset Management LLC purchased a new stake in Omeros during the 1st quarter valued at $357,000. Trexquant Investment LP bought a new stake in Omeros during the first quarter worth about $88,000. Hsbc Holdings PLC purchased a new position in shares of Omeros in the 1st quarter worth about $142,000. Wellington Management Group LLP purchased a new position in shares of Omeros in the 1st quarter worth about $1,118,000. Finally, Nuveen LLC purchased a new stake in Omeros in the first quarter worth approximately $938,000. 48.79% of the stock is owned by institutional investors.

Omeros Stock Performance

Shares of Omeros stock traded down $0.06 on Thursday, hitting $3.16. The stock had a trading volume of 569,591 shares, compared to its average volume of 667,872. The stock has a 50 day moving average of $6.55 and a 200 day moving average of $8.10. Omeros has a twelve month low of $2.97 and a twelve month high of $13.60. The firm has a market capitalization of $185.15 million, a P/E ratio of -1.37 and a beta of 2.42.

Omeros (NASDAQ:OMER - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.05). Equities analysts expect that Omeros will post -3.09 earnings per share for the current year.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.